Morphologic changes induced by thio-TEPA were examined in animals with chemically induced neoplasms. Both toxic and metabolic effects were documented. Degeneration, vacuolization and increased exfoliation (toxic) were most prominent, occurred within 48 hours of exposure, and tended to subside after removal of the drug. Nuclear changes (metabolic) were rare and occurred late. Neither toxic nor metabolic effects were specific for thio-TEPA: both could be detected in control animals receiving saline. The metabolic effects of thio-TEPA are not sufficiently widespread to prevent tumor growth.

Animals↗

PubMedDate not supplied

Morphologic effects of thio-TEPA on mouse urothelium.

The urothelial changes induced by intravesical instillation of thio-TEPA into experimental animals were studied by cytologic, light microscopic, and electron microscopic techniques. Cells and tissue from treated and untreated groups were compared using a total of 54 discriminators. There were few consistent differences. Cells with marked nuclear atypia were not identified. The results indicate that thio-TEPA has little effect on non-diseased bladders. The atypical cells occasionally present in specimens from thio-TEPA treated bladders apparently do no emanate from normal urothelium.

Animals↗

PubMedDate not supplied

Cytology of ileal conduit urine.

Explore the source record for details and available documents.

Carcinoma, Squamous Cell↗

PubMedDate not supplied

Phase I-II study of mitomycin C topical therapy for low-grade, low stage transitional cell carcinoma of the bladder: an interim report.

Intravesical mitomycin C therapy was administered to 63 patients with noninvasive bladder carcinoma in a phase I-II study. Doses ranged from 20 to 60 mg once a week for 8 weeks. The overall response rate was 67% including a complete remission rate of 45%. The median duration of complete remission for the two lowest dose groups was > 14 months, with a range of 1-36+ months. Followup is not yet adequate to determine the median duration of complete remission for the higher dose groups. No bone marrow suppression or other systemic toxic effects were noted. Adverse effects were localized and occurred infrequently. No mitomycin C was detected in serial serum samples after intravesical instillation.

Absorption↗